JP2022527556A - プロテインアルギニンメチルトランスフェラーゼ５の選択的阻害剤 - Google Patents

プロテインアルギニンメチルトランスフェラーゼ５の選択的阻害剤 Download PDF

Info

Publication number
JP2022527556A
JP2022527556A JP2021559254A JP2021559254A JP2022527556A JP 2022527556 A JP2022527556 A JP 2022527556A JP 2021559254 A JP2021559254 A JP 2021559254A JP 2021559254 A JP2021559254 A JP 2021559254A JP 2022527556 A JP2022527556 A JP 2022527556A
Authority
JP
Japan
Prior art keywords
methyl
alkyl
amino
arc
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021559254A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527556A5 (https=
Inventor
リン，ホン
ルエンゴ，フアン
シェティ，ルパ
ホーキンス，マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prelude Therapeutics Inc
Original Assignee
Prelude Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prelude Therapeutics Inc filed Critical Prelude Therapeutics Inc
Publication of JP2022527556A publication Critical patent/JP2022527556A/ja
Publication of JP2022527556A5 publication Critical patent/JP2022527556A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021559254A 2019-04-05 2020-04-03 プロテインアルギニンメチルトランスフェラーゼ５の選択的阻害剤 Pending JP2022527556A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962830019P 2019-04-05 2019-04-05
US62/830,019 2019-04-05
PCT/US2020/026625 WO2020206289A1 (en) 2019-04-05 2020-04-03 Selective inhibitors of protein arginine methyltransferase 5

Publications (2)

Publication Number Publication Date
JP2022527556A true JP2022527556A (ja) 2022-06-02
JP2022527556A5 JP2022527556A5 (https=) 2023-04-07

Family

ID=72666997

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021559254A Pending JP2022527556A (ja) 2019-04-05 2020-04-03 プロテインアルギニンメチルトランスフェラーゼ５の選択的阻害剤

Country Status (4)

Country Link
US (1) US20220152072A1 (https=)
EP (1) EP3952874A4 (https=)
JP (1) JP2022527556A (https=)
WO (1) WO2020206289A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025520530A (ja) * 2022-07-15 2025-07-03 アビスコ セラピューティクス カンパニー リミテッド Ｐｒｍｔ５阻害剤、その製造方法及び薬学における応用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
US12403137B2 (en) 2019-10-28 2025-09-02 Tango Therapeutics, Inc. Compounds and methods of use
WO2022026892A1 (en) 2020-07-31 2022-02-03 Tango Therapeutics, Inc. Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers
JP2024508235A (ja) * 2021-02-04 2024-02-26 アムジエン・インコーポレーテツド 三環－アミド－二環ｐｒｍｔ５阻害剤
US20240262857A1 (en) * 2021-05-27 2024-08-08 Emory University Novel universal anti-rna virus agents
CN113546173B (zh) * 2021-08-19 2022-08-23 徐州医科大学 Prmt5抑制剂在制备治疗冠状病毒感染所引起的疾病的药物中的应用
WO2024170488A1 (en) 2023-02-13 2024-08-22 Astrazeneca Ab Prmt5 inhibitor for use in cancer therapy
EP4553080A1 (en) * 2023-11-07 2025-05-14 Ustav Organicke Chemie a Biochemie AV CR, v.v.i. Nucleoside derivatives as antiviral agents against coronaviruses
US20250313552A1 (en) * 2024-04-04 2025-10-09 New Frontier Bio, Inc. Nicotinate esters and therapeutic methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019032859A1 (en) * 2017-08-09 2019-02-14 Prelude Therapeutics, Incorporated SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
ES2334924T3 (es) * 2005-03-17 2010-03-17 Proyecto De Biomedicina Cima, S.L. Empleo de 5'-metiltioadenosina (mta) en la prevencion y/o tratamiento de enfermedades autoinmunes y/o rechazo de trasplantes.
PT2231689T (pt) * 2008-01-18 2016-10-07 Inst Of Organic Chemistry And Biochemistry Of The Acad Of Sciences Of The Czech Republic Novos nucleósidos 7-deazapurina citostáticos
KR20120113228A (ko) * 2009-12-18 2012-10-12 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 베타 세포 복제 촉진 화합물 및 그 사용 방법
US20170198006A1 (en) * 2014-06-25 2017-07-13 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2016079321A1 (en) * 2014-11-20 2016-05-26 Cemm Forschungszentrum Für Molekulare Medizin Gmbh Antagonists of setdb2 for use in the therapy of infectious diseases
TWI870767B (zh) * 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
WO2017120508A1 (en) * 2016-01-08 2017-07-13 Arcus Biosciences, Inc. Modulators of 5'-nucleotidase, ecto and the use thereof
WO2018081451A1 (en) * 2016-10-26 2018-05-03 Indiana University Research And Technology Corporation Small molecule protein arginine methyltransferase 5 (prmt5) inhibitors and methods of treatment
US12552826B2 (en) * 2018-08-07 2026-02-17 Merck Sharp & Dohme Llc PRMT5 inhibitors
US11981701B2 (en) * 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019032859A1 (en) * 2017-08-09 2019-02-14 Prelude Therapeutics, Incorporated SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025520530A (ja) * 2022-07-15 2025-07-03 アビスコ セラピューティクス カンパニー リミテッド Ｐｒｍｔ５阻害剤、その製造方法及び薬学における応用

Also Published As

Publication number Publication date
EP3952874A4 (en) 2022-12-28
EP3952874A1 (en) 2022-02-16
WO2020206289A1 (en) 2020-10-08
US20220152072A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
JP2022527556A (ja) プロテインアルギニンメチルトランスフェラーゼ５の選択的阻害剤
CN111527099B (zh) 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂
RU2534613C2 (ru) Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения
CN117729920A (zh) 可用作myt1抑制剂的甲酰胺吡咯并吡嗪和吡啶化合物及其在治疗癌症中的用途
US12440506B2 (en) Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
JP7328241B2 (ja) タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤
WO2018152548A1 (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
JP2025503422A (ja) Ｐｄ－ｌ１を標的とするための方法及び組成物
WO2018160855A1 (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EP4188930B1 (en) Substituted heterocyclic compounds and therapeutic uses thereof
WO2020206308A1 (en) Selective inhibitors of protein arginine methyltransferase 5
CN110845560A (zh) 苯丙氨酸酰胺化的核苷酸衍生物及其制备方法与应用
KR102776475B1 (ko) 아민, 아미드 및 페놀 전달에 유용한 프로드러그 플랫폼
HK40067540A (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EA040066B1 (ru) Селективные ингибиторы протеин-аргинин-метилтрансферазы 5 (prmt5)
HK40031042B (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
HK40031042A (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EA042008B1 (ru) Селективные ингибиторы белка аргининметилтрансферазы 5 (prmt5)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240507

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241126